688331 荣昌生物
2025/122024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)25.367-54.148-35.907-23.7067.847
总资产报酬率 ROA (%)11.135-26.633-26.170-19.6236.675
投入资产回报率 ROIC (%)13.140-31.295-30.278-22.3017.336

边际利润分析
销售毛利率 (%)87.28080.36277.43264.76695.175
营业利润率 (%)22.227-84.786-138.651-128.90021.245
息税前利润/营业总收入 (%)23.845-81.479-140.043-138.15418.503
净利润/营业总收入 (%)21.828-85.526-139.547-129.36419.368

收益指标分析
经营活动净收益/利润总额(%)8.708102.862102.567112.85863.826
价值变动净收益/利润总额(%)89.5660.188-0.462-1.2120.000
营业外收支净额/利润总额(%)-1.7180.8650.6420.359-9.692

偿债能力分析
流动比率 (X)1.4291.0511.9763.6633.758
速动比率 (X)1.1910.7481.3183.0673.300
资产负债率 (%)50.21063.87837.82317.28717.138
带息债务/全部投入资本 (%)39.28854.41224.6532.1684.113
股东权益/带息债务 (%)149.57078.335295.1394,368.3852,265.230
股东权益/负债合计 (%)99.16456.550164.386478.465483.513
利息保障倍数 (X)11.958-20.133282.44815.718-21.383

营运能力分析
应收账款周转天数 (天)44.63571.40583.05747.6380.583
存货周转天数 (天)574.923747.907931.109531.299906.380